Search Results
Your search for ,maY matches 16901 pages
Showing 6601 - 6650Selpercatinib for Lung and Thyroid Cancers With RET Gene Mutations or Fusions
On may 8, 2020, selpercatinib was granted accelerated approval for the following indications: Adult patients with metastatic RET fusion-positive non–small cell lung cancer (NSCLC) Adult and pediatric patients ≥ 12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer who...
Expert Point of View: Scott T. Tagawa, MD, MS
Discussant Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, agreed that prostate-specific membrane antigen (PSMA)-targeted positron-emission tomography (PET) is the wave of the future, but data on long-term outcomes are needed, he said. “We are all aware of the deficiencies of imaging ...
Leora Horn, MD, on Thoracic Cancer and COVID-19: How Type of Cancer Therapy May Affect Survival
Leora Horn, MD, of Vanderbilt University, discusses the results of the TERAVOLT study, launched by the Thoracic Cancers International COVID-19 Collaboration. It examined the impact of specific chemotherapy and immunotherapy regimens on hospitalization and risk of death in patients with thoracic...
Ibrutinib in Combination With Rituximab in Chronic Lymphocytic Leukemia
On April 21, 2020, ibrutinib was granted an expanded indication for use in combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1,2 The recommended dosage of ibrutinib in CLL/SLL is 420 mg, once daily,...
Cancer and COVID-19: Considerations About Neutropenia, Anemia, and Thrombocytopenia
GUEST EDITORS Dr. Abutalib is Associate Director of the Hematology and Cellular Therapy Program and Director of the Clinical Apheresis Program at Cancer Treatment Centers of America, Zion, Illinois; Associate Professor at the Roseland Franklin University of Medicine and Science; and Founder and...
In Biochemically Recurrent Prostate Cancer, PSMA-Targeted PET/CT Imaging May Be Useful
Positron-emission tomography/computed tomography (PET/CT) imaging with the prostate-specific membrane antigen (PSMA)-targeted radiotracer fluorine F-18 DCFPyL (PyL) successfully identified areas of occult metastasis in men with biochemically recurrent metastatic castration-resistant prostate...
Olaparib Plus Bevacizumab in Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
On May 8, 2020, olaparib was granted an expanded indication to include use in combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line...
Relationship Between Type 3c Diabetes and Pancreatic Cancer
According to the results of a European case-control study published by Molina-Montes et al in the journal Gut, one of the most recently identified types of diabetes—type 3c, or pancreatogenic diabetes—could also be an early manifestation of pancreatic cancer. Pancreatic cancer has a high mortality...
Rates of Testicular Cancer Rising Among Racial/Ethnic Minorities in the United States
Between 2001 and 2016 in the United States, Asian/Pacific Islander men experienced the greatest increase in the incidence of testicular germ cell tumors, followed by Hispanic and American Indian/Alaska Native men, according to a study published by Ghazarian et al in Cancer Epidemiology, Biomarkers...
Outcomes With Minimally Invasive vs Open Esophagectomy in Routine Practice
In a Dutch study reported in the Journal of Clinical Oncology, Markar et al found that routine use of minimally invasive vs open esophagectomy for esophageal cancer was associated with increased risk of pulmonary complications and other adverse outcomes, contrary to the findings of the clinical...
Sacituzumab Govitecan-hziy for Previously Treated Metastatic Triple-Negative Breast Cancer
On April 22, 2020, the antibody-drug conjugate sacituzumab govitecan-hziy was granted accelerated approval for treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.1,2 Supporting Efficacy Data Approval was...
Expert Point of View: Padmanee Sharma, MD, PhD
Discussant of the IMbassador250 trial, Padmanee Sharma, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, said: “These data indicate that neither anti–PD-1/PD-L1 monotherapy or the combination of anti–PD-1/PD-L1 with enzalutamide is likely to provide improved clinical benefit ...
IMbassador250 Trial: No Survival Benefit With Atezolizumab and Enzalutamide in Metastatic Prostate Cancer
The addition of the checkpoint inhibitor atezolizumab to enzalutamide failed to improve overall survival compared with enzalutamide alone in men with metastatic castration-resistant prostate cancer in the phase III IMbassador250 trial, according to results presented at the 2020 American Association ...
PSA Level Prior to Salvage Radiotherapy: Tailoring Delivery of ADT to Men With Prostate Cancer Most Likely to Benefit
In a recent article in JAMA Oncology, reviewed in this issue of The ASCO Post, Dess et al present an important analysis to help guide decision-making in the setting of salvage radiotherapy in prostate cancer.1 This secondary analysis assessed the association of prostate-specific antigen (PSA)...
Presalvage Radiotherapy PSA Levels and Outcomes With Long-Term Antiandrogen Therapy in Prostate Cancer
In an analysis from the NRG/RTOG 9601 trial reported in JAMA Oncology,1Robert T. Dess, MD, of the Department of Radiation Oncology, University of Michigan, Ann Arbor, and colleagues found that men with higher prostate-specific antigen (PSA) presalvage radiotherapy levels after prostatectomy had a...
Addition of CD38-Directed Antibody Isatuximab to Multiple Myeloma Armamentarium
The treatment approaches to multiple myeloma have significantly changed over the past decade with the introduction of many new active agents. Among them, the monoclonal antibodies have been one of the most exciting advances in myeloma, complementing their success in other hematologic cancers. In...
Study Explores Adding Trastuzumab to Radiotherapy for Women With HER2-Positive DCIS
The addition of trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) in the NRG Oncology clinical trial NSABP B-43. The trial did find a modest (19%) reduction ...
Nivolumab vs Bevacizumab in Recurrent Glioblastoma
As reported in JAMA Oncology by David A. Reardon, MD, and colleagues, the phase III CheckMate 143 trial showed no difference in overall survival among adult patients with a first recurrence of glioblastoma treated with nivolumab vs bevacizumab following standard radiation and temozolomide therapy. ...
RET Kinase Inhibitor for Patients With Solid Tumors and RET Genetic Fusions
The RET inhibitor pralsetinib showed activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the phase I/II ARROW trial, presented by Vivek Subbiah, MD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 109). “This trial shows...
Trastuzumab Deruxtecan vs Chemotherapy for Previously Treated Patients With HER2-Positive Advanced Gastric Cancer
Results of the phase II DESTINY-Gastric01 study—reported at the ASCO20 Virtual Scientific Program (Abstract 4513) and published in The New England Journal of Medicine, by Kohei Shitara, MD, of the National Cancer Center Hospital East, Kashiwa, and colleagues—found that the antibody-drug conjugate...
Lutetium-177–Labeled PSMA-617 Improves PSA Response in First Analysis From TheraP Trial in Metastatic Prostate Cancer
Initial results of the randomized phase II TheraP trial show that therapy directed to prostate-specific membrane antigen (PSMA) with lutetium-177–labeled PSMA-617 (LuPSMA) significantly improved prostate-specific antigen (PSA) response compared with cabazitaxel in men with metastatic...
Does Treatment With Immune Checkpoint Inhibitors Cause Flare-ups in Patients With Preexisting IBD or Microscopic Colitis?
In a retrospective analysis reported in JCO Oncology Practice, Grover et al found that enterocolitis flares occurred in approximately one-quarter of patients with preexisting inflammatory bowel disease (IBD) or microscopic colitis who received immune checkpoint inhibitors for the treatment of solid ...
International Medical and Radiation Oncologist Balances Cancer Research and Clinical Practice
The Revolutions of 1989 that resulted in the end of communist rule in Central and Eastern Europe and beyond began in Poland. Perhaps if not for that social upheaval, the career of internationally renowned oncologist Jacek Jassem, MD, PhD, would have taken a very different path. Dr. Jassem had fled...
ASCO’s President Aims to Ensure Equitable Cancer Care for Every Patient
The desire to pursue a career in medicine took root when Lori J. Pierce, MD, FASTRO, FASCO, was a young child visiting family in segregated Ahoskie, North Carolina. She witnessed firsthand the impact the town’s lone African American family physician had on the community. When it came time to...
Standard vs Histology-Tailored Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcoma
As reported in the Journal of Clinical Oncology by Alessandro Gronchi, MD, and colleagues, final results of a phase III trial conducted by the Italian, French, and Polish Sarcoma Groups showed no disease-free or overall survival benefit with use of histology-tailored vs standard...
IMvigor130: First-Line Atezolizumab Plus Chemotherapy vs Chemotherapy Alone in Advanced Urothelial Cancer
As reported in The Lancet by Matthew D. Galsky, MD, of Icahn School of Medicine at Mount Sinai, and colleagues, the phase III IMvigor130 trial has shown prolonged progression-free survival with first-line atezolizumab plus platinum-based chemotherapy vs platinum-based chemotherapy alone in patients ...
Reflections of an ASCO President: Science vs Practice
My year as President was a busy one. Aside from continuing my research and directing the activities of the National Surgical Adjuvant Breast and Bowel Project, I was drowned by the vast amount of information that was sent to me by ASCO headquarters. At the onset of my Presidency, I discovered a...
Tribute to Bernard Fisher, MD
Bernard Fisher, MD, who died on October 16, 2019, at the age of 101, is recognized today for his groundbreaking research in breast cancer, which ultimately ended the standard practice of performing the Halsted radical mastectomy, a treatment that had been in place for more than 75 years. His...
Love of Science, Passion for Research, and Belief in the Power of the Immune System
Steven A. Rosenberg, MD, PhD, FASCO, knew from the start of his medical career that if treatments for cancer were to become curative, research in new therapies would have to move away from the mainstay one-size-fits-all approach of systemic chemotherapy to an innovative, personalized strategy that ...
Love of Science and a Family Tragedy Set the Course for This Breast Cancer Researcher
When oncology luminary Joyce A. O’Shaughnessy, MD, was in her early teens, her youngest sister, Teri, developed acute lymphocytic leukemia at age 5. Dr. O’Shaughnessy, the oldest of four girls, recalled that her sister’s struggle with the disease had a profound effect on her worldview. “Teri went...
Ivosidenib Plus Venetoclax With or Without Azacitidine for IDH1-Mutated AML
Combination therapy with the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosenidib plus the BCL2 inhibitor venetoclax with or without the chemotherapeutic agent azacitidine showed activity in patients with IDH1-mutated acute myeloid leukemia (AML) in a phase Ib/II trial. The results of the...
HIF2A Inhibitor for von Hippel-Lindau Disease–Associated Renal Cell Carcinoma
In an international trial, treatment with MK-6482, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease–associated renal cell carcinoma (RCC). The results of the phase II trial were shared ...
Tepotinib Shows Activity in Patients With NSCLC and MET Exon 14–Skipping Mutation
Patients with advanced non–small cell lung cancer (NSCLC) and a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study presented during the ASCO20 Virtual Scientific Program...
Data From TAPUR Study Cohorts on Olaparib for BRCA-Mutated Advanced Prostate and Pancreatic Cancers
Positive results from two cohorts of the Targeted Agent and Profiling Utilization Registry (TAPUR) study provide real-world evidence to support recent clinical trial data that demonstrate a role for olaparib in the treatment of advanced prostate and pancreatic cancers with BRCA1/2-inactivating...
Is Sentinel Lymph Node Biopsy Alone Oncologically Safe for Patients With Early-Stage Cervical Cancer?
In a study of patients with early-stage cervical cancer presented by Balaya et al during the Gynecologic Cancer Oral Abstract Session of the ASCO20 Virtual Scientific Program (Abstract 6006), researchers assessed disease-free and disease-specific survival to determine whether sentinel lymph node...
FDA Approves First-Line Ramucirumab Plus Erlotinib for Metastatic EGFR-Mutated NSCLC
On May 29, the U.S. Food and Drug Administration (FDA) approved ramucirumab (Cyramza, injection, 10 mg/mL solution) in combination with erlotinib for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19...
FDA Approves Atezolizumab Plus Bevacizumab for Patients With Unresectable or Metastatic HCC
On May 29, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The review of this application...
Transoral Resection Followed by Low-Dose Radiation for Some Oropharyngeal Cancers
The final results of the randomized phase II ECOG-ACRIN E3311 trial were presented by Robert L. Ferris, MD, PhD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 6500) and in today's Head and Neck Cancer Oral Abstract Session. The trial, conducted in patients undergoing...
First-Line Pembrolizumab Plus Etoposide/Platinum for Extensive-Stage Small Cell Lung Cancer
As reported at the ASCO20 Virtual Scientific Program by Charles M. Rudin, MD, PhD, and colleagues (Abstract 9001), the phase III KEYNOTE-604 trial has shown that first-line pembrolizumab plus etoposide/platinum significantly prolonged progression-free survival and prolonged overall survival at a...
Tucatinib Combination in Previously Treated HER2-Positive Metastatic Breast Cancer With Brain Metastases
In an analysis of the pivotal phase III HER2CLIMB trial to be reported at the ASCO20 Virtual Scientific Program, Nancy U. Lin, MD, and colleagues found that tucatinib, a small-molecule tyrosine kinase inhibitor that is highly selective for HER2, plus trastuzumab/capecitabine significantly improved...
TROPHIMMUN Trial Finds Avelumab Effective in Rare Gynecologic Tumor Resistant to Chemotherapy
The first trial of immunotherapy for gestational trophoblastic tumors proved effective in almost 50% of patients resistant to single-agent chemotherapy, French investigators reported in an abstract presented during the ASCO20 Virtual Scientific Program.1 The results of the phase II TROPHIMMUN trial ...
Study Finds Patients With Lung Cancer Infected With COVID-19 Are at High Risk for Hospitalization
Data from the global TERAVOLT Consortium, which is investigating the impact of COVID-19 infection on patients with thoracic cancers, have found that these patients are at high risk for hospitalization and death. Prior use of chemotherapy was associated with an increased risk of mortality, as was...
Adjuvant Osimertinib in Early-Stage EGFR-Positive NSCLC
Adjuvant osimertinib significantly improved disease-free survival compared with placebo in patients with stage IB to IIIA EGFR-mutated non–small cell lung cancer (NSCLC) who underwent complete resection of primary tumor and received chemotherapy if indicated. These results from the first interim...
Lymphoma: Many Questions, Too Few Answers
The successful treatment of malignant lymphoma has been one of the great achievements in medical oncology, but certainly more work is needed to define key biologic targets as well as molecular markers for a more accurate definition of prognosis following therapy. In day-to-day practice, unanswered...
Why The ASCO Post?
It has been 5 years since ASCO has been part of a new publication, the last being the Journal of Oncology Practice (JOP). As the ASCO Board and leadership evaluated the publication mix we recognized there was a gap that needed to be filled. The Journal of Clinical Oncology (JCO), now 25 years old, ...
Pembrolizumab Doubles Progression-Free Survival in MSI-H/dMMR Metastatic Colorectal Cancer
For the first time, upfront treatment with immunotherapy has improved—in fact, doubled—median progression-free survival in a subset of patients with metastatic colorectal cancer. The findings are from the interim analysis of the randomized open-label phase III KEYNOTE-177 trial comparing the...
Maintenance Avelumab Improves Survival in Advanced Bladder Cancer
Maintenance therapy with avelumab and best supportive care significantly prolonged overall survival vs best supportive care alone in patients with advanced urothelial carcinoma that did not progress on first-line platinum-based chemotherapy, according to an interim analysis of the phase III...
Sources for Better GVHD-Free Relapse-Free Survival After Adult Alternative Donor HCT
In a retrospective study of registry data reported in the Journal of Clinical Oncology, Mehta et al identified alternative donor sources for hematopoietic cell transplantation (HCT) that were associated with better graft-vs-host disease (GVHD)-free (GRFS) and chronic GVHD–free (CRFS) relapse-free...
Use of Symptom Assessment Scale vs Routine Management in Patients With Cancer Receiving Radiotherapy
In a single-institution study reported in JCO Oncology Practice, Goyal et al found that use of the Edmonton Symptom Assessment Scale (ESAS) self-assessment tool during weekly on-treatment physician visits was associated with reduced symptom severity vs routine symptom management in patients...
